Galactomannan Test in Suspected Invasive Pulmonary Aspergillosis Patients: An Evidence-Based Case Report
DOI:
https://doi.org/10.36497/jri.v45i4.954Keywords:
diagnosis, galactomannan, invasive pulmonary aspergillosisAbstract
Background: Invasive pulmonary aspergillosis is a severe fungal infection with a high mortality rate. However, because the clinical and radiological images are non-specific, and culture results take a long time and yield unsatisfactory results, rapid, high-accuracy tests are needed. Consequently, the diagnosis of invasive pulmonary aspergillosis remains difficult. The objective of this study was to assess the galactomannan (GM) test as a diagnostic tool for patients with suspected invasive pulmonary aspergillosis.
Methods: Articles were searched through three databases (PubMed, Embase, and Cochrane) using keywords based on PICO components related to suspected invasive pulmonary aspergillosis and the GM test. Titles and abstracts were screened, duplicates were removed, and articles were filtered according to inclusion and exclusion criteria. The critical appraisal was performed using methods recommended by the Center for Evidence-Based Medicine at the University of Oxford.
Results: Three studies reported serum GM test sensitivities ranging from 71% to 88%, suggesting that this assay may be suitable as a screening tool due to its adequate true positive detection rate. The specificity values in these studies ranged from 89% to 98%, indicating good accuracy in correctly identifying true negative cases. However, considerable heterogeneity was observed across the studies.
Conclusion: The GM test is a promising rapid diagnostic tool for suspected invasive pulmonary aspergillosis, enabling earlier and more accurate antifungal treatment. However, further studies are needed to standardize its cut-off values and interpretation to ensure consistent clinical application.
Downloads
References
1. Naaraayan A, Kavian R, Lederman J, Basak P, Jesmajian S. Invasive pulmonary aspergillosis – case report and review of literature. J Community Hosp Intern Med Perspect. 2015;5(1):26322.
2. Marr KA, Seidel K, Slavin MA, Bowden RA, Gary Schoch H, Flowers MED, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96(6):2055–61.
3. Chen L, Wang Y, Zhang T, Li Y, Meng T, Liu L, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: A meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18(1):155.
4. Garcia-Vidal C, Peghin M, Cervera C, Gudiol C, Ruiz-Camps I, Moreno A, et al. Causes of death in a contemporary cohort of patients with invasive aspergillosis. PLoS One. 2015;10(3):e0120370.
5. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490–526.
6. Bukkems LMP, van Dommelen L, Regis M, van den Heuvel E, Nieuwenhuizen L. The Use of Galactomannan Antigen Assays for the Diagnosis of Invasive Pulmonary Aspergillosis in the Hematological Patient: A Systematic Review and Meta-Analysis. Journal of Fungi. 2023;9(6):674.
7. Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021;51(S7):143–76.
8. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clinical Infectious Diseases. 2006;42(10):1417–27.
9. Ramanan P, Wengenack NL, Theel ES. Laboratory diagnostics for fungal infections: A review of current and future diagnostic assays. Clin Chest Med. 2017;38(3):535–54.
10. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clinical Infectious Diseases. 2016;63(4):e1–60.
11. Haydour Q, Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, et al. Diagnosis of fungal infections a systematic review and meta-analysis supporting American thoracic society practice guideline. Ann Am Thorac Soc. 2019;16(9):1179–88.
12. Li C, Sun L, Liu Y, Zhou H, Chen J, She M, et al. Diagnostic value of bronchoalveolar lavage fluid galactomannan assay for invasive pulmonary aspergillosis in adults: A meta-analysis. J Clin Pharm Ther. 2022;47(12):1913–22.
13. De Heer K, Gerritsen MG, Visser CE, Leeflang MMG. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Database of Systematic Reviews. 2019;2019(5):CD012399.
14. Zhou W, Li H, Zhang Y, Huang M, He Q, Li P, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol. 2017;55(7):2153–61.
15. Sehgal IS, Dhooria S, Choudhary H, Aggarwal AN, Garg M, Chakrabarti A, et al. Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis. J Clin Microbiol. 2019;57(3):e01821-18.
16. Okuturlar Y, Ozkalemkas F, Ener B, Serin SO, Kazak E, Ozcelik T, et al. Serum galactomannan levels in the diagnosis of invasive aspergillosis. Korean Journal of Internal Medicine. 2015;30(6):899–905.
17. Leeflang MMG, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJPM, Hooft L, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database of Systematic Reviews. 2015;2017(9):CD007394.
18. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clinical Infectious Diseases. 2005;40(12):1762–9.
19. Mercier T, Guldentops E, Lagrou K, Maertens J. Galactomannan, a surrogate marker for outcome in invasive aspergillosis: Finally coming of age. Front Microbiol. 2018;9(APR):661.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lina Rahmiati, Mubarokah, Dimas Seto Prasetyo
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
